The study provides evidence that costs for women with lymphedema remain significantly elevated long after cancer treatment. On average, there is a US $500–$1215 difference. These economic burdens occur even among those who have health insurance.
Although women with and without lymphedema experience a similar number of economically burdensome events and comorbidities, high out-of-pocket costs for women with breast cancer-related lymphedema lead to a cascade of other economic challenges that persist long after cancer treatment. Future work should explore patient-driven recommendations to reduce economic burden after cancer